AstraZeneca Forxiga meets primary endpoint for type 2 diabetes Ruchika Sharma8 Oct 2023 10:00 AM ISTCambridge: AstraZeneca has announced positive results from the T2NOW Phase III trial, one of the largest paediatric type 2 diabetes studies performed...
AstraZeneca settles Nexium, Prilosec product liability litigations for USD 425 million Ruchika Sharma4 Oct 2023 1:30 PM ISTAstraZeneca has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. The agreements effectively...
AstraZeneca gets CDSCO Panel Nod to study asthma drug Benralizumab Dr. Divya Colin22 Sept 2023 6:00 PM ISTNew Delhi: Pharmaceutical major, AstraZeneca has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
AstraZeneca rare disease unit acquires Pfizer portfolio for USD 1 billion Ruchika Sharma22 Sept 2023 2:25 PM ISTAstraZeneca's Rare-Disease Unit
AstraZeneca Enhertu recommended for nod in EU by CHMP for HER2-mutant advanced non-small cell lung cancer Ruchika Sharma16 Sept 2023 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for...
AstraZeneca seeks to calm CEO speculation after shares drop Ruchika Sharma12 Sept 2023 4:30 PM ISTLondon: AstraZeneca appeared to play down speculation about the future of its CEO after its shares fell more than 4% on Monday following a...
AstraZeneca declares positive results from trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer Ruchika Sharma12 Sept 2023 1:30 PM ISTCambridge: AstraZeneca has announced positive results from FLAURA2 phase III trial of Tagrisso (osimertinib) in combination with chemotherapy for...
Alveoair spirometer earns USFDA clearance for distribution in US Ruchika Sharma9 Sept 2023 3:54 PM ISTPune: Alveofit (Roundworks Technologies Private Limited) has announced that its groundbreaking product, alveoair spirometer, has earned U.S. FDA...
AstraZeneca Calquence approved in China for chronic lymphocytic leukaemia Ruchika Sharma5 Sept 2023 11:55 AM ISTCambridge: AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in...
AstraZeneca-Daiichi Sankyo Enhertu gets two breakthrough therapy designations in US for multiple HER2 expressing cancers Ruchika Sharma3 Sept 2023 4:00 PM ISTTokyo: Daiichi Sankyo has announced that ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations...
AstraZeneca Soliris approved in Japan for paediatric patients with generalised myasthenia gravis Ruchika Sharma29 Aug 2023 4:14 PM ISTCambridge: AstraZeneca's Soliris (eculizumab) has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis...
AstraZeneca's Lynparza plus abiraterone approved in Japan for treatment of BRCA-mutated metastatic castration-resistant prostate cancer Ruchika Sharma26 Aug 2023 11:30 AM ISTCambridge: AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of...
